Table 2 Signal strength of PTs of TAM-related thromboembolism in FAERS database.
From: Real-world assessment of thromboembolic risk associated with tamoxifen
PT | n | ROR (95% Cl) | PRR (χ2) | IC (IC025) | EBGM (EBGM05) |
|---|---|---|---|---|---|
Arterial thromboembolism (SMQ) | |||||
Ischaemic stroke | 20 | 4.88 (3.15–7.57) | 4.88 (61.58) | 2.28 (1.65) | 4.87 (3.37) |
Peripheral artery thrombosis | 12 | 36.87 (20.88–65.11) | 36.84 (414.58) | 5.19 (4.39) | 36.51 (22.69) |
Blindness transient | 7 | 4.20 (2.00–8.81) | 4.19 (17.01) | 2.07 (1.05) | 4.19 (2.25) |
Retinal artery occlusion | 6 | 10.80 (4.85–24.07) | 10.79 (53.18) | 3.43 (2.34) | 10.77 (5.51) |
Coronary artery embolism | 3 | 44.05 (14.12–137.45) | 44.04 (124.8) | 5.45 (3.99) | 43.57 (16.81) |
Venous thromboembolism (SMQ) | |||||
Pulmonary embolism | 123 | 5.59 (4.68–6.67) | 5.54 (458.26) | 2.47 (2.21) | 5.54 (4.77) |
Deep vein thrombosis | 79 | 5.17 (4.14–6.45) | 5.14 (263.54) | 2.36 (2.04) | 5.14 (4.27) |
Cerebral venous thrombosis | 24 | 58.10 (38.82–86.97) | 58.00 (1325.13) | 5.84 (5.26) | 57.18 (40.8) |
Pulmonary thrombosis | 10 | 4.06 (2.18–7.54) | 4.05 (22.98) | 2.02 (1.15) | 4.05 (2.41) |
Portal vein thrombosis | 9 | 12.54 (6.52–24.13) | 12.53 (95.19) | 3.64 (2.73) | 12.49 (7.22) |
Superior sagittal sinus thrombosis | 7 | 36.91 (17.53–77.71) | 36.89 (242.20) | 5.19 (4.17) | 36.56 (19.61) |
Embolism venous | 6 | 8.89 (3.99–19.82) | 8.89 (41.92) | 3.15 (2.06) | 8.87 (4.54) |
Thrombophlebitis | 6 | 7.23 (3.24–16.11) | 7.23 (32.13) | 2.85 (1.76) | 7.21 (3.69) |
Jugular vein thrombosis | 6 | 14.98 (6.72–33.40) | 14.98 (77.96) | 3.90 (2.81) | 14.92 (7.63) |
Budd-Chiari syndrome | 5 | 88.50 (36.47–214.75) | 88.47 (422.98) | 6.44 (5.24) | 86.56 (41.23) |
Retinal vein occlusion | 5 | 7.93 (3.30–19.07) | 7.93 (30.21) | 2.98 (1.80) | 7.91 (3.80) |
Venous thrombosis limb | 5 | 9.62 (4.00–23.15) | 9.62 (38.53) | 3.26 (2.08) | 9.60 (4.61) |
Mesenteric vein thrombosis | 4 | 17.64 (6.61–47.11) | 17.64 (62.49) | 4.13 (2.84) | 17.56 (7.72) |
Subclavian vein thrombosis | 4 | 14.93 (5.59–39.87) | 14.93 (51.79) | 3.89 (2.60) | 14.88 (6.54) |
Transverse sinus thrombosis | 4 | 32.23 (12.05–86.24) | 32.22 (120.04) | 5.00 (3.70) | 31.97 (14.03) |
Superficial vein thrombosis | 4 | 29.81 (11.15–79.73) | 29.80 (110.51) | 4.89 (3.59) | 29.59 (12.99) |
Ophthalmic vein thrombosis | 3 | 55.84 (17.86–174.53) | 55.82 (159.28) | 5.78 (4.33) | 55.06 (21.22) |
Vena cava thrombosis | 3 | 7.78 (2.51–24.16) | 7.78 (17.7) | 2.96 (1.51) | 7.77 (3.01) |
Axillary vein thrombosis | 3 | 36.04 (11.56–112.33) | 36.03 (101.26) | 5.16 (3.71) | 35.72 (13.8) |
Unspecified thromboembolism (SMQ) | |||||
Thrombosis | 62 | 3.35 (2.61–4.30) | 3.34 (101.6) | 1.74 (1.37) | 3.34 (2.71) |
Monoplegia | 8 | 7.94 (3.97–15.89) | 7.93 (48.38) | 2.99 (2.02) | 7.92 (4.43) |
Antiphospholipid syndrome | 6 | 16.93 (7.59–37.76) | 16.93 (89.53) | 4.08 (2.98) | 16.86 (8.62) |
Atrial thrombosis | 3 | 6.12 (1.97–18.99) | 6.12 (12.82) | 2.61 (1.17) | 6.11 (2.37) |
